Novartis shares Sandoz H1 results ahead of spin-off


ZURICH, Sept 5 (Reuters) - Novartis NOVN.S on Tuesday published half year results for Sandoz and confirmed it plans to spin-off its generic medicines division on Oct. 4.

Sandoz achieved net third-party sales of $4.8 billion in the first half of the year, driven by an increase in volume, which was partly offset by negative price affects.

Guidance for 2023 and the mid-term, from 2024 to 2028, was also confirmed.

(Reporting by Noele Illien; Editing by Christian Schmollinger)

((; +41 41 528 39 73;))

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


More Related Articles

Info icon

This data feed is not available at this time.

Sign up for Smart Investing to get the latest news, strategies and tips to help you invest smarter.